Erythrodermic cutaneous T cell lymphoma with hypereosinophilic syndrome: Treatment with interferon alfa and extracorporeal photopheresis

International Journal of Dermatology

Volumn 46, Issue 11, 2007, Pages 1198-1204

  Lee, Catherine H ^b   Mamelak, Adam J ^b   Vonderheid, Eric C ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CORTICOSTEROID; ERYTHROMYCIN; PSORALEN; STEROID;

ADULT; ARTICLE; BONE MARROW BIOPSY; CARDIOMYOPATHY; CASE REPORT; CLINICAL PROTOCOL; CONGESTIVE HEART FAILURE; CUTANEOUS T CELL LYMPHOMA; DERMATITIS; DISEASE ASSOCIATION; EOSINOPHIL; HOSPITALIZATION; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMMUNOHISTOCHEMISTRY; MALE; MYCOSIS FUNGOIDES; PROGNOSIS; PUVA; REMISSION; SKIN BIOPSY;

CYTOKINES; EOSINOPHILIA; HUMANS; HYPEREOSINOPHILIC SYNDROME; INTERFERON-ALPHA; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; PHOTOPHERESIS; SKIN NEOPLASMS; T-LYMPHOCYTE SUBSETS;

EID: 35848945723     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2007.03190.x     Document Type: Article

References (58)

1. Tefferi A. Blood eosinophilia: A new paradigm in disease classification, diagnosis, and treatment. Mayo Clin Proc 2005; 80: 75-83.
2. Löffler W. Endocarditis parietalis fibroplastica mit bluteosinophilie. Schweiz Med Wochenschr 1936; 65: 817-820.
3. Hardy WR, Anderson RE. The hypereosinophilic syndromes. Ann Intern Med 1968; 68: 1220-1229.
4. Chusid MJ, Dale DC, West BC, et al. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Med Baltimore 1975; 54: 1-27.
5. Adamko DJ, Odemuyiwa SO, Vethanayagam D, et al. The rise of the phoenix: the expanding role of the eosinophil in health and disease. Allergy 2005; 60: 13-22.
6. Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy 2004; 59: 673-689.
7. Wilkins HJ, Crane MM, Copeland K, et al. Hypereosinophilic syndrome: An update. Am J Hematol 2005; 80: 148-157.
8. Gleich GJ, Leiferman KM. The hypereosinophilic syndromes: Still more heterogeneity. Curr Opin Immunol 2005; 17: 679-684.
9. Gotlib J, Cools J, Malone JM III, et al. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: Implications for diagnosis, classification, and management. Blood 2004; 103: 2879-2891.
10. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004; 104: 3038-3045.
11. Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 2004; 18: 734-742.
12. La Starza R, Specchia G, Cuneo A, et al. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del (4) (q12) -FIP1L1/ PDGFRA but not genomic rearrangements of other tyrosine kinases. Haematologica 2005; 90: 596-601.
13. Roche-Lestienne C, Lepers S, Soenen-Cornu V, et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 2005; 19: 792-798.
14. Cogan E, Schandene L, Crusiaux A, et al. Clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 1994; 330: 535-538.
15. Simon HU, Plotz SG, Dummer R, et al. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Eng J Med 1999; 341: 1112-1120.
16. Roufosse F, Schandene L, Sibille C, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol 2000; 109: 540-548.
17. Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005; 115: 798-812.
18. Tendler CL, et al. Abnormal cytokine expression in Sézary and adult T-cell leukemia cells correlates with the functional diversity between these T-cell malignancies. Cancer Res 1994; 54: 4430-4435.
19. Dummer R, et al. Sézary syndrome, T-helper 2 cytokines and accessory factor-1 (AF-1). Leuk Lymphoma 1998; 28: 515-522.
20. Suchin KB, Cassin M, Gottleib SL, et al. Increased interleukin 5 production in eosinophilic Sézary syndrome: Regulation by interferon alfa and interleukin 12. J Am Acad Dermatol 2001; 44: 28-32.
21. Vowels BR, Cassin M, Vonderheid EC, et al. Aberrant cytokine production by Sézary syndrome patients: Cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992; 99: 90-94.
22. Sausville EA, Eddy JL, Makuch RW, et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome: definition of three distinctive prognostic groups. Ann Intern Med 1988; 109: 372-382.
23. Tancrède-Bohin E, Ionescu MA, de La Salmonière P, et al. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas. Arch Dermatol 2004; 140: 1057-1061.
24. Ionescu MA, Rivet J, Daneshpouy M, et al. In situ eosinophil activation in 26 primary cutaneous T-cell lymphomas with blood eoinophilia. J Am Acad Dermatol 2005; 52: 32-39.
25. Bagot M, Bodemer C, Wechsler J, et al. Nonepidermotropic T lymphoma preceded for several years by hypereosinophilic syndrome. Ann Dermatol Venereol 1990; 117: 883-885.
26. Butterfield JH. Diverse clinical outcomes of eosinophilic patients with T-cell receptor gene rearrangements: The emerging diagnostic importance of molecular genetics testing. Am J Hematol 2001; 68: 81-86.
27. + cells with a Th2-like pattern of cytokine production in the peripheral blood of a patient with cutaneous T cell lymphoma. Leukemia 1997; 11: 1983-1985.
28. Vonderheid EC, Sobel EL, Nowell PC, et al. Diagnostic and prognostic significance of Sézary cells in peripheral blood smears from patients with cutaneous T cell lymphoma. Blood 1985; 66: 358-366.
29. Morice WG, Katzmann JA, Pittelkow MR, et al. A comparison of morphologic features, flow cytometry, TCR-Vbeta analysis, and TCR-PCR in qualitative and quantitative assessment of peripheral blood involvement by Sézary syndrome. Am J Clin Pathol 2006; 125: 364-374.
30. Abel EA, Lindae ML, Hoppe RT, et al. Benign and malignant forms of erythroderma: Cutaneous immunophenotypic characteristics. J Am Acad Dermatol 1988; 19: 1089-1095.
31. Vonderheid EC. On the diagnosis of erythrodermic cutaneous T-cell lymphoma. J Cutan Pathol 2006; 33: 27-42.
32. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83: 2759-2779.
33. Kazmierowski JA, Chusid MJ, Parrillo JE, et al. Dermatologic manifestations of the hypereosinophilic syndrome. Arch Dermatol 1978; 114: 531-535.
34. Dereure O, Meyer F, Ciurana A-J, et al. Dermatologic manifestations of idiopathic hypereosinophilic syndrome: An unusual observation with protracted course and literature review. Eur J Dermatol 1994; 4: 110-116.
35. Weller PF. The idiopathic hypereosinophilic syndrome. Arch Dermatol 1996; 132: 583-585.
36. Plötz SG, Simon HU, Ring J. Skin manifestations in hypereosinophilic syndrome (HES) - symptoms, therapy and pathophysiology. Allergologie 1999; 21: 489-496.
37. Roufosse F, Simonart T, Cogan E. Skin lesions as the only manifestation of the idiopathic hypereosinophilic syndrome. Br J Dermatol 2001; 144: 639.
38. Lee M-L, Fischer G, Gow E. Hypereosinophilic syndrome presenting with erythroderma. Australas J Dermatol 1988; 29: 95-101.
39. May LP, Kelly J, Sanchez M. Hypereosinophilic syndrome with unusual cutaneous manifestations in two men with HIV infection. J Am Acad Dermatol 1990; 23: 202-204.
40. Launay D, Catteau B, Dubost-Brama A, et al. A four-year history of pruriginous erythroderma leading to the diagnosis of idiopathic hypereosinophilic syndrome. Acta Derm Venereol 2002; 82: 376-378.
41. Granjo E, Lima M, Lopes JM, et al. Chronic eosinophilic leukaemia presenting with erythroderma, mild eosinophilia and hyper-IgE: Clinical, immunological and cytogenetic features and therapeutic approach. Acta Haematol 2002; 107: 108-112.
42. Plötz S-G, Simon H-U, Darsow U, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003; 349: 2334-2339.
43. Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003; 101: 3391-3397.
44. Musto P, Falcone A, Sanpaolo G, et al. Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis. Leuk Lymphoma 2004; 45: 1219-1222.
45. Vonderheid EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: Report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002; 46: 95-106.
46. Simon HU, Dummer R. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia (author reply). N Eng J Med 1999; 342: 660-661.
47. Guitart J. Idiopathic eosinophilia. N Engl J Med 2000; 342: 659-660.
48. Fujita H, Asahina A, Sugaya M, et al. Differential production of Th1- and Th2-type chemokines by mouse Langerhans cells and splenic dendritic cells. J Invest Dermatol 2005; 124: 343-350.
49. Woerly G, Roger N, Loiseau S, et al. Expression of Th1 and Th2 immunoregulatory cytokines by human eosinophils. Int Arch Allergy Immunol 1999; 118: 95-97.
50. Broxmeyer HE, Cooper S, Rubin BY, et al. The synergistic influence of human interferon-gamma and interferon-alpha on suppression of hematopoietic progenitor cells is additive with the enhanced sensitivity of these cells to inhibition by interferons at low oxygen tension in vitro. J Immunol 1985; 135: 2502-2506.
51. Nadarajah S, Krafchik B, Roifman C, et al. Treatment of hypereosinophilic syndrome in a child using cyclosporine: Implication for a primary T-cell abnormality. Pediatrics 1997; 99: 630-633.
52. Catterall MD, Addis BJ, Smith JL, et al. Sézary syndrome: transformation to a high grade T-cell lymphoma after treatment with cyclosporine A. Clin Exp Dermatol 1983; 8: 159-169.
53. Thomsen K, Lange Wantzin G. Extracutaneous spreading with fatal outcome of mycosis fungoides in a patient treated with cyclosporin A. A word of caution. Dermatologica 1987; 174: 236-238.
54. Chiappelli F, Manfrini E, Franceschi C, et al. Steroid regulation of cytokines. Relevance for TH1-to-TH2 shift? Ann N Y Acad Sci 1994; 746: 204-215.
55. Kovalovsky D, Refojo D, Holsboer F, et al. Molecular mechanisms and Th1/ Th2 pathways in corticosteroid regulation of cytokine production. J Neuroimmunol 2000; 109: 23-29.
56. Thomas M, Chandi SM, George S, et al. Sézary syndrome - unmasked by cyclosporine. Int J Dermatol 1998; 37: 957-958.
57. Sutton SA, Assa'ad AH, Rothenberg ME. Anti-IL-5 and hypereosinophilic syndrome. Clin Immunol 2005; 115: 51-60.
58. Heshmati F. Mechanisms of action of extracorporeal photochemotherapy. Transfus Apher Sci 2003; 29: 61-70.